查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886062

全球免疫组织化学市场

Immunohistochemistry
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 168 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球免疫组织化学市场预计2030年将达到45亿美元。

全球免疫组织化学市场在2024年预计为30亿美元，预计到2030年将达到45亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为7.1%。本报告分析的细分市场之一－抗体市场，预期复合年增长率为7.2%，到分析期末将达到19亿美元。设备细分市场预计在分析期间内复合年增长率为6.2%。

美国市场规模估计为8.247亿美元，而中国市场预计将以6.6%的复合年增长率成长。

据估计，2024年美国免疫组织化学市场规模将达8.247亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到6.916亿美元，在2024年至2030年的分析期内，复合年增长率（CAGR）为6.6%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，两国的复合年增长率分别为6.7%和5.8%。在欧洲，德国的复合年增长率预计约为5.8%。

全球免疫组织化学（IHC）市场—主要趋势与驱动因素概述

为什么免疫组织化学（IHC）在疾病诊断和研究中变得越来越重要

免疫组织化学（IHC）利用标记抗体来检测组织中的特定抗原，正日益成为疾病诊断、临床研究和治疗发展的重要工具。该技术结合了解剖学、免疫学和生物化学方法，能够可视化特定蛋白质的分布和定位，为细胞和组织生物学提供重要见解。 IHC广泛应用于肿瘤学领域，用于检测和分类癌细胞，使病理学家能够诊断各种癌症类型、评估疾病严重程度并确定最佳治疗策略。识别乳癌中的HER2、ER和PR以及肺癌中的PD-L1等生物标记的能力，可以指南标靶治疗和个人化治疗策略，使IHC成为现代病理学和精准医学中不可或缺的工具。

慢性疾病（尤其是癌症）的日益普及是推动全球免疫组化（IHC）市场发展的主要因素之一。随着全球癌症发生率的持续上升，人们对能够区分癌症亚型并预测患者对特定治疗方法的精准可靠的诊断工具的需求日益增长。 IHC 也被广泛应用于神经病理学领域，用于识别阿兹海默症和帕金森氏症等神经退化性疾病，以及心血管疾病和感染疾病的研究。该技术能够提供组织内蛋白质表达的空间和背景信息，并且兼容多种组织样本（包括切片检查和手术标本），因此其应用范围正在不断扩大，涵盖多个治疗领域。随着全球医疗保健系统越来越重视疾病早期检测和个人化医疗，对先进 IHC 解决方案的需求预计将显着增长。

哪些技术进步正在推动免疫组织化学的发展和广泛应用？

技术创新彻底改变了免疫组织化学领域，使其更加精准、高效，并适用于更广泛的应用。其中最具变革性的创新之一是自动化免疫组织化学平台的开发，该平台实现了从样本製备、抗体孵育到洗涤和检测的整个染色过程的自动化。自动化最大限度地减少了人为误差，确保了结果的一致性，并缩短了周转时间，使免疫组织化学更加可靠和可重复。罗氏BenchMark系列和Dako Autosterner等自动化免疫组织化学平台已成为高通量检查室的必备工具，使其能够在保持高诊断品质的同时高效处理大量检体。将数位影像分析软体整合到自动化平台中，进一步提高了免疫组织化学工作流程的效率，使病理学家能够更精确地观察、量化和解读染色模式。

另一项重要进展是多重免疫组化（IHC）技术的发展，该技术能够同时检测单一组织切片上的多种生物标记。传统的IHC技术每张切片只能分析一到两种标记物，难以研究不同细胞类型和讯号路径之间的复杂相互作用。多重IHC技术透过使用多种一抗（每种一抗都与不同的显色或萤光报告分子偶联）来克服这一局限性，从而在天然组织环境中可视化多种蛋白质。这项技术使研究人员能够更深入研究肿瘤微环境、免疫细胞浸润和生物标记共表达模式。诸如顺序染色和条码等新型多重技术的发展，进一步增强了IHC在研究和临床应用中的效用，有助于识别预测性和预后性生物标誌物，并促进对疾病机制的理解。

先进检测系统的引入，例如基于聚合物和奈米技术的检测方法，正在提高免疫组化（IHC）的灵敏度和特异性。基于聚合物的检测系统无需生物素，并减少了特异性结合和背景染色。同时，基于奈米技术的方法增强了讯号放大，从而能够更清晰地检测低表达蛋白。合成抗体和重组抗体的使用提高了IHC试剂的一致性和性能，确保了结果的可靠性和可重复性。此外，人工智慧（AI）和机器学习（ML）在数位病理学中的应用正在变革IHC结果的分析和解读。 AI驱动的影像分析软体能够自动识别感兴趣区域、量化染色强度并对组织样本进行分类，从而减轻病理学家的工作负担，并实现更准确、更标准化的评估。这些技术进步不仅增强了IHC的功能和可靠性，也拓展了其应用范围，使其成为研究、诊断和个人化医疗领域的强大工具。

市场动态与监管标准如何影响免疫组织化学市场？

免疫组织化学市场受多种因素的复杂影响，包括市场力量、监管标准和医疗保健趋势，这些因素共同影响着产品的开发、应用和商业化。其中一个关键的市场驱动因素是慢性疾病（尤其是癌症）的日益普遍，这推动了对更有效的诊断和预后评估工具的需求。癌症是全球发病率和死亡率的主要原因，因此迫切需要准确的诊断方法来指导治疗决策和监测疾病进展。免疫组织化学 (IHC) 广泛应用于肿瘤学领域，用于检测指示癌症类型、分级和潜在治疗反应的生物标记。随着标靶治疗和免疫疗法的日益普及，IHC 越来越多地被用于识别能够从这些治疗中获益最大的患者，从而推动精准医疗的发展。此外，IHC 在心血管疾病、自体免疫和神经退化性疾病等领域的应用不断扩展，也促进了市场成长。

监管标准和合规要求在塑造免疫组织化学市场方面也发挥关键作用。美国食品药物管理局(FDA)、欧洲药品管理局 (EMA) 和其他区域性监管机构等，已製定严格的指南，用于指导免疫组织化学 (IHC) 检测的开发、测试和商业化，以确保其安全性、有效性和可靠性。遵守这些法规对于製造商获得市场进入并维持医疗服务提供者和患者的信任至关重要。监管环境正在不断发展，以应对免疫组织化学检测的复杂性，尤其是在伴随诊断方面。伴随诊断用于识别最有可能对特定标靶治疗产生反应的患者。伴随诊断通常需要与相应的治疗药物共同开发和共同核准，这进一步增加了监管流程的复杂性。免疫组织化学检测在个人化医疗中日益广泛的应用，促使监管机构完善其指南，以确保免疫组织化学检测能够提供具有临床意义的信息，从而支持治疗决策。

市场动态，包括製造商竞争、技术创新和医疗报销政策，都会影响免疫组织化学市场。竞争格局的特点是，成熟的生命科学公司、诊断公司和专业试剂供应商都在致力于开发新的免疫组织化学解决方案，力求在提高灵敏度和特异性的同时，兼顾易用性。各公司透过产品创新、整合数位病理学和人工智慧技术，以及提供包含抗体、检测系统和自动化平台在内的综合性免疫组织化学解决方案来脱颖而出。医疗报销政策和支付方的核保决策会影响免疫组织化学检测的普及，因为报销通常决定了这些产品的可近性和可负担性。报销环境因地区而异，并受到检测的临床效用、替代诊断方案的可用性以及整体医疗预算等因素的影响。对于在免疫组织化学市场中运作的公司而言，了解这些市场动态和监管标准至关重要，这有助于它们满足全球患者和医疗服务提供者的未满足诊断需求，并扩大市场份额。

推动免疫组织化学市场扩张的关键成长要素是什么？

全球免疫组织化学市场成长主要受以下几个关键因素驱动：癌症诊断需求的不断增长、免疫组织化学技术的进步以及个人化医疗的日益普及。其中一个关键成长要素是癌症发生率的上升，这显着增加了对能够提供肿瘤生物学详细资讯并辅助治疗决策的诊断工具的需求。免疫组织化学广泛应用于肿瘤学领域，用于检测可用于肿瘤分类、预测疾病进展和识别潜在治疗标靶的生物标记。标靶治疗和免疫疗法的日益普及也增加了对伴随诊断的需求，其中许多伴随诊断依赖免疫组织化学来确定生物标记的表达水平，并识别可能受益于特定治疗的患者。随着全球癌症负担的持续加重和个人化医疗的日益普及，对先进免疫组织化学解决方案的需求预计将进一步增长。

另一个关键的成长要素是免疫组织化（IHC）技术的持续进步，这不断拓展了该技术的功能和应用范围。多重IHC、数位病理学和人工智慧驱动的影像分析等创新技术正在提高IHC的准确性、效率和临床效用。多重IHC能够同时检测单一组织切片上的多种生物标记物，从而更全面地了解组织微环境，并有助于阐明复杂的生物学交互作用。数位病理学正在改变IHC结果的分析和解读方式，使病理学家能够在电脑萤幕上可视化组织样本，进行定量分析，并与同事共用影像以进行远端会诊。人工智慧和机器学习的应用透过实现染色强度的自动量化、组织模式的分类和疾病预后的预测，进一步改进了IHC结果的解读。这些技术进步使IHC更加强大和易用，从而促进了其在研究和临床领域的应用。

人们对个人化医疗日益增长的兴趣也推动了免疫组织化学市场的扩张。个人化医疗旨在根据每位患者独特的基因和分子特征优化治疗策略。免疫组织化学在这过程中发挥关键作用，它能够提供与疾病预后和治疗反应相关的关键生物标记表达资讯。例如，免疫组织化学可用于检测乳癌中HER2、肺癌中PD-L1和淋巴瘤中CD20的表达，从而指导标靶治疗和免疫疗法的应用。人们对个人化医疗日益增长的兴趣正在推动新型免疫组织化学检测方法和伴随诊断技术的开发，以支持个人化的治疗决策。将免疫组织化学与其他分子技术（例如次世代定序（NGS）和液态生物检体）相结合，可以从分子和细胞层面更全面地了解疾病，进一步增强免疫组织化学在个人化医疗中的效用。

最后，免疫组织化学在研发领域的应用不断扩展，也推动了市场成长。免疫组织化学广泛应用于临床前研究，用于分析蛋白质表现和定位、阐明疾病机制以及评估治疗药物对组织的影响。它也被用于临床试验，以评估新药的动态并识别可作为替代终点的生物标记。随着製药和生技公司持续加大研发投入，对免疫组织化学试剂、抗体和检测系统的需求预计将会增加。此外，免疫组织化学在肿瘤以外的其他疾病（例如神经退化性疾病、心血管疾病和感染疾病）研究中的应用日益广泛，也扩大了市场范围。在技​​术进步、应用领域不断扩展以及对精准诊断和标靶治疗日益重视的推动下，全球免疫组织化学市场预计将持续成长，製造商将不断创新以满足不断变化的医疗需求，同时满足肿瘤学、研究和个人化医疗等关键领域的持续需求。

部分：

依产品（抗体、器械、试剂、试剂盒）、应用（诊断、药物检测）、最终用途（医院/诊断检查室、研究机构、其他最终用途）分类

受访公司范例

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Bio Sb, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • MilliporeSigma
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Market Glass, Inc. 并没有采用查询LLM 或产业专用的SLM 的常见做法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括影片文字稿、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP12536

Global Immunohistochemistry Market to Reach US$4.5 Billion by 2030

The global market for Immunohistochemistry estimated at US$3.0 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Antibodies, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Equipment segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$824.7 Million While China is Forecast to Grow at 6.6% CAGR

The Immunohistochemistry market in the U.S. is estimated at US$824.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.6 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Immunohistochemistry (IHC) Market - Key Trends & Drivers Summarized

Why Is Immunohistochemistry (IHC) Gaining Prominence in Disease Diagnosis and Research?

Immunohistochemistry (IHC) is becoming a critical tool in disease diagnosis, clinical research, and therapeutic development due to its ability to detect specific antigens in tissues using labeled antibodies. This technique combines anatomical, immunological, and biochemical methods to visualize the distribution and localization of specific proteins, providing essential insights into cellular and tissue biology. IHC is widely used in oncology for the detection and classification of tumor cells, enabling pathologists to diagnose various types of cancers, assess the severity of the disease, and determine the best course of treatment. The ability to identify biomarkers such as HER2, ER, and PR in breast cancer, or PD-L1 in lung cancer, helps guide targeted therapies and personalized treatment strategies, making IHC an indispensable tool in modern pathology and precision medicine.

The growing prevalence of chronic diseases, particularly cancer, is one of the primary drivers of the global IHC market. As the global incidence of cancer continues to rise, there is an increasing need for accurate and reliable diagnostic tools that can differentiate between cancer subtypes and predict patient responses to specific therapies. IHC is also extensively used in neuropathology for the identification of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as in cardiovascular and infectious disease research. The technique’s ability to provide spatial and contextual information about protein expression in tissues, combined with its compatibility with a wide range of tissue samples, including biopsies and surgical specimens, is expanding its use across multiple therapeutic areas. As healthcare systems worldwide place a greater emphasis on early disease detection and personalized medicine, the demand for advanced IHC solutions is expected to increase significantly.

What Technological Advancements Are Driving the Evolution and Adoption of Immunohistochemistry?

Technological advancements are revolutionizing the field of immunohistochemistry, making it more accurate, efficient, and accessible for a broad range of applications. One of the most transformative innovations is the development of automated IHC platforms, which automate the entire staining process, from sample preparation and antibody incubation to washing and detection. Automation minimizes human error, ensures consistency, and reduces turnaround times, making IHC more reliable and reproducible. Automated IHC platforms such as the Roche BenchMark series and the Dako Autostainer have become essential tools in high-throughput laboratories, enabling the efficient processing of large numbers of samples while maintaining high diagnostic quality. The integration of digital imaging and analysis software with automated platforms is further enhancing the efficiency of IHC workflows, enabling pathologists to visualize, quantify, and interpret staining patterns with greater precision.

Another significant advancement is the development of multiplex IHC techniques, which allow for the simultaneous detection of multiple biomarkers on a single tissue section. Traditional IHC is limited to the analysis of one or two markers per slide, making it challenging to study complex interactions between different cell types or signaling pathways. Multiplex IHC overcomes this limitation by using multiple primary antibodies, each labeled with distinct chromogenic or fluorescent reporters, to visualize multiple proteins in their native tissue context. This capability is enabling researchers to investigate tumor microenvironments, immune cell infiltration, and biomarker co-expression patterns in greater detail. The development of novel multiplexing technologies, such as sequential staining and barcoding, is further enhancing the utility of IHC in research and clinical applications, supporting the identification of predictive and prognostic biomarkers and advancing our understanding of disease mechanisms.

The incorporation of advanced detection systems, such as polymer-based and nanotechnology-based detection methods, is also improving the sensitivity and specificity of IHC. Polymer-based detection systems eliminate the need for biotin, reducing non-specific binding and background staining, while nanotechnology-based methods enhance signal amplification, enabling the detection of low-abundance proteins with greater clarity. The use of synthetic and recombinant antibodies is improving the consistency and performance of IHC reagents, ensuring that the results are more reliable and reproducible. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in digital pathology is transforming the analysis and interpretation of IHC results. AI-driven image analysis software can automatically identify regions of interest, quantify staining intensity, and classify tissue samples, reducing the burden on pathologists and enabling more accurate and standardized assessments. These technological advancements are not only enhancing the capabilities and reliability of IHC but are also expanding its application possibilities, making it a powerful tool for research, diagnostics, and personalized medicine.

How Are Market Dynamics and Regulatory Standards Shaping the Immunohistochemistry Market?

The immunohistochemistry market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of chronic diseases, particularly cancer, which is driving the demand for more effective diagnostic and prognostic tools. Cancer is a leading cause of morbidity and mortality worldwide, creating a significant need for accurate diagnostics that can guide treatment decisions and monitor disease progression. IHC is widely used in oncology to detect biomarkers that are indicative of cancer type, grade, and potential response to therapies. The rising adoption of targeted therapies and immunotherapies is further increasing the use of IHC to identify patients who are most likely to benefit from these treatments, supporting the trend toward precision medicine. Additionally, the expanding applications of IHC in areas such as cardiovascular, autoimmune, and neurodegenerative diseases are contributing to the growth of the market.

Regulatory standards and compliance requirements are also playing a critical role in shaping the immunohistochemistry market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, testing, and commercialization of IHC tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to address the complexity of IHC tests, particularly in the context of companion diagnostics, which are used to identify patients who are most likely to respond to specific targeted therapies. Companion diagnostics often require co-development and simultaneous approval with the corresponding therapeutic agent, making the regulatory pathway more complex. The growing use of IHC in personalized medicine is encouraging regulatory agencies to refine their guidelines to ensure that IHC tests provide clinically meaningful information that can support treatment decisions.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the immunohistochemistry market. The competitive landscape is characterized by the presence of established life sciences companies, diagnostic firms, and specialized reagent providers, each striving to develop novel IHC solutions that offer enhanced sensitivity, specificity, and ease of use. Companies are differentiating themselves through product innovation, the integration of digital pathology and AI technologies, and the ability to provide comprehensive IHC solutions that include antibodies, detection systems, and automated platforms. Healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of IHC tests, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the immunohistochemistry market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Immunohistochemistry Market?

The growth in the global immunohistochemistry market is driven by several key factors, including the increasing demand for cancer diagnostics, advancements in IHC technology, and the growing adoption of personalized medicine. One of the primary growth drivers is the rising incidence of cancer, which is creating a significant need for diagnostic tools that can provide detailed information about tumor biology and guide treatment decisions. IHC is widely used in oncology for the detection of biomarkers that can classify tumors, predict disease progression, and identify potential therapeutic targets. The growing use of targeted therapies and immunotherapies is increasing the demand for companion diagnostics, many of which rely on IHC to determine biomarker expression levels and identify patients who are likely to benefit from specific treatments. As the global burden of cancer continues to rise and as the adoption of personalized medicine increases, the demand for advanced IHC solutions is expected to grow.

Another significant growth driver is the ongoing advancement of IHC technology, which is expanding the capabilities and applications of the technique. Innovations such as multiplex IHC, digital pathology, and AI-driven image analysis are enhancing the accuracy, efficiency, and clinical utility of IHC. Multiplex IHC enables the simultaneous detection of multiple biomarkers on a single tissue section, providing a more comprehensive view of the tissue microenvironment and supporting the investigation of complex biological interactions. Digital pathology is transforming the way IHC results are analyzed and interpreted, allowing pathologists to visualize tissue samples on a computer screen, perform quantitative analysis, and share images with colleagues for remote consultation. The use of AI and machine learning is further enhancing the interpretation of IHC results by enabling automated quantification of staining intensity, classification of tissue patterns, and prediction of disease outcomes. These technological advancements are making IHC more powerful and accessible, supporting its adoption in both research and clinical settings.

The increasing focus on personalized medicine is also fueling the expansion of the immunohistochemistry market. Personalized medicine aims to tailor treatment strategies to individual patients based on their unique genetic and molecular profiles. IHC plays a critical role in this approach by providing information on the expression of key biomarkers that are associated with disease prognosis and response to treatment. For example, IHC is used to detect the expression of HER2 in breast cancer, PD-L1 in lung cancer, and CD20 in lymphoma, guiding the use of targeted therapies and immunotherapies. The growing emphasis on personalized medicine is encouraging the development of new IHC assays and companion diagnostics that can support individualized treatment decisions. The integration of IHC with other molecular techniques, such as next-generation sequencing (NGS) and liquid biopsy, is further enhancing its utility in personalized medicine by providing a more comprehensive view of the disease at both the molecular and cellular levels.

Lastly, the expanding applications of immunohistochemistry in research and drug development are contributing to the growth of the market. IHC is widely used in preclinical research to study protein expression and localization, investigate disease mechanisms, and evaluate the effects of potential therapeutic agents on tissues. The technique is also used in clinical trials to assess the pharmacodynamics of new drugs and to identify biomarkers that can serve as surrogate endpoints. As pharmaceutical and biotechnology companies continue to invest in research and development, the demand for IHC reagents, antibodies, and detection systems is expected to rise. Additionally, the increasing use of IHC in disease research beyond oncology, such as in neurodegenerative diseases, cardiovascular disorders, and infectious diseases, is expanding the market’s reach. As demand from key sectors such as oncology, research, and personalized medicine continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global immunohistochemistry market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on precision diagnostics and targeted therapies.

SCOPE OF STUDY:

The report analyzes the Immunohistochemistry market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibodies, Equipment, Reagents, Kits); Application (Diagnostics, Drug Testing); End-Use (Hospitals & Diagnostic Laboratories, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 31 Featured) -

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Bio Sb, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • MilliporeSigma
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Immunohistochemistry - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Cancer Diagnostics Drives Growth in Immunohistochemistry Market
    • Expansion of Research in Molecular Pathology Spurs Adoption of Immunohistochemistry Techniques
    • Growth in Focus on Targeted Therapies and Precision Medicine Expands Addressable Market for IHC
    • Role of Immunohistochemistry in Biomarker Detection and Cancer Subtyping Strengthens Business Case for Adoption
    • Growth in Use of IHC for Neurological and Infectious Disease Research Expands Market Opportunities
    • Technological Integration for Multiplexed IHC and Digital Pathology Expands Market Potential
    • Increasing Focus on IHC for Companion Diagnostics in Oncology Expands Addressable Market
    • Role of IHC in Enhancing Tissue-based Diagnostics and Personalized Medicine Strengthens Market Demand
    • Growth in Use of Immunohistochemistry in Drug Development and Clinical Trials Expands Market Reach
    • Growth in Use of IHC for Infectious Disease Detection and Surveillance Fuels Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Immunohistochemistry Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Drug Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION